Jundishapur Journal of Microbiology

Published by: Kowsar

A Recombinant Chimera Protein as a Novel Brucella Subunit Vaccine: Protective Efficacy and Induced Immune Response in BALB/c Mice

Abbas Abdollahi 1 , Shahla Mansouri 1 , * , Jafar Amani 2 , Mahdi Fasihi-Ramandi 3 , Reza Ranjbar 3 , Amir Ghasemi 4 and Mohammad Moradi 1
Authors Information
1 Department of Microbiology, Kerman University of Medical Sciences, Kerman, IR Iran
2 Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
4 Departments of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, IR Iran
Article information
  • Jundishapur Journal of Microbiology: January 2018, 11 (1); e12776
  • Published Online: November 14, 2017
  • Article Type: Research Article
  • Received: May 7, 2016
  • Accepted: June 24, 2017
  • DOI: 10.5812/jjm.12776

To Cite: Abdollahi A, Mansouri S, Amani J, Fasihi-Ramandi M, Ranjbar R, et al. A Recombinant Chimera Protein as a Novel Brucella Subunit Vaccine: Protective Efficacy and Induced Immune Response in BALB/c Mice, Jundishapur J Microbiol. 2018 ; 11(1):e12776. doi: 10.5812/jjm.12776.

Abstract
Copyright © 2017, Jundishapur Journal of Microbiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
6. Conclusion
Acknowledgements
Footnotes
References
  • 1. Seleem MN, Boyle SM, Sriranganathan N. Brucellosis: a re-emerging zoonosis. Vet Microbiol. 2010;140(3-4):392-8. doi: 10.1016/j.vetmic.2009.06.021. [PubMed: 19604656].
  • 2. Fugier E, Pappas G, Gorvel JP. Virulence factors in brucellosis: implications for aetiopathogenesis and treatment. Expert Rev Mol Med. 2007;9(35):1-10. doi: 10.1017/S1462399407000543. [PubMed: 18088444].
  • 3. Pappas G. The changing Brucella ecology: novel reservoirs, new threats. Int J Antimicrob Agents. 2010;36 Suppl 1:S8-11. doi: 10.1016/j.ijantimicag.2010.06.013. [PubMed: 20696557].
  • 4. Nicoletti P. Brucellosis: past, present and future. Prilozi. 2010;31(1):21-32. [PubMed: 20703181].
  • 5. Avila-Calderon ED, Lopez-Merino A, Sriranganathan N, Boyle SM, Contreras-Rodriguez A. A history of the development of Brucella vaccines. Biomed Res Int. 2013;2013:743509. doi: 10.1155/2013/743509. [PubMed: 23862154].
  • 6. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet Microbiol. 2002;90(1-4):479-96. [PubMed: 12414166].
  • 7. Martins Rda C, Irache JM, Gamazo C. Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease. Expert Rev Vaccines. 2012;11(1):87-95. doi: 10.1586/erv.11.172. [PubMed: 22149711].
  • 8. Perkins SD, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans. FEMS Microbiol Rev. 2010;34(3):379-94. doi: 10.1111/j.1574-6976.2010.00211.x. [PubMed: 20180858].
  • 9. Yang X, Skyberg JA, Cao L, Clapp B, Thornburg T, Pascual DW. Progress in Brucella vaccine development. Front Biol (Beijing). 2013;8(1):60-77. doi: 10.1007/s11515-012-1196-0. [PubMed: 23730309].
  • 10. Olsen SC. Recent developments in livestock and wildlife brucellosis vaccination. Rev Sci Tech. 2013;32(1):207-17. [PubMed: 23837378].
  • 11. Zhao Z, Yan F, Ji W, Luo D, Liu X, Xing L, et al. Identification of immunoreactive proteins of Brucella melitensis by immunoproteomics. Sci China Life Sci. 2011;54(9):880-7. doi: 10.1007/s11427-011-4218-2. [PubMed: 21922434].
  • 12. He Y, Xiang Z. Bioinformatics analysis of Brucella vaccines and vaccine targets using VIOLIN. Immunome Res. 2010;6 Suppl 1. S5. doi: 10.1186/1745-7580-6-S1-S5. [PubMed: 20875156].
  • 13. Costa Oliveira S, Costa Macedo G, Augusto de Almeida L, Souza de Oliveira F, Onate A, Cassataro J, et al. Recent Advances in Understanding Immunity Against Brucellosis: Application for Vaccine Development. Open Vet Sci J. 2010;4(1):102-8. doi: 10.2174/1874318801004010102.
  • 14. Dorneles EM, Sriranganathan N, Lage AP. Recent advances in Brucella abortus vaccines. Vet Res. 2015;46:76. doi: 10.1186/s13567-015-0199-7. [PubMed: 26155935].
  • 15. He Y. Analyses of Brucella Pathogenesis, Host Immunity, and Vaccine Targets using Systems Biology and Bioinformatics. Front Cel Infect Microbiol. 2012;2. doi: 10.3389/fcimb.2012.00002.
  • 16. Deuerling E, Patzelt H, Vorderwulbecke S, Rauch T, Kramer G, Schaffitzel E, et al. Trigger Factor and DnaK possess overlapping substrate pools and binding specificities. Mol Microbiol. 2003;47(5):1317-28. [PubMed: 12603737].
  • 17. Yang X, Walters N, Robison A, Trunkle T, Pascual DW. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine. 2007;25(12):2261-8. doi: 10.1016/j.vaccine.2006.12.004. [PubMed: 17239499].
  • 18. Ghasemi A, Salari MH, Zarnani AH, Pourmand MR, Ahmadi H, Shirazi MH, et al. Immunogenicity assessment of Brucella mellitensis HSP and TF proteins by immunized rabbit serum. Iran J Allergy Asthma Immunol. 2013;12(2):192-4. [PubMed: 23754360].
  • 19. Wang W, Wu J, Qiao J, Weng Y, Zhang H, Liao Q, et al. Evaluation of humoral and cellular immune responses to BP26 and OMP31 epitopes in the attenuated Brucella melitensis vaccinated sheep. Vaccine. 2014;32(7):825-33. doi: 10.1016/j.vaccine.2013.12.028. [PubMed: 24370708].
  • 20. Grillo MJ, Marin CM, Barberan M, de Miguel MJ, Laroucau K, Jacques I, et al. Efficacy of bp26 and bp26/omp31 B. melitensis Rev.1 deletion mutants against Brucella ovis in rams. Vaccine. 2009;27(2):187-91. doi: 10.1016/j.vaccine.2008.10.065. [PubMed: 19007836].
  • 21. Gupta VK, Radhakrishnan G, Harms J, Splitter G. Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis. Vaccine. 2012;30(27):4017-22. doi: 10.1016/j.vaccine.2012.04.036. [PubMed: 22546330].
  • 22. Estein SM, Fiorentino MA, Paolicchi FA, Clausse M, Manazza J, Cassataro J, et al. The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams. Vaccine. 2009;27(48):6704-11. doi: 10.1016/j.vaccine.2009.08.097. [PubMed: 19748579].
  • 23. Cassataro J, Pasquevich KA, Estein SM, Laplagne DA, Zwerdling A, de la Barrera S, et al. A DNA vaccine coding for the chimera BLSOmp31 induced a better degree of protection against B. ovis and a similar degree of protection against B. melitensis than Rev.1 vaccination. Vaccine. 2007;25(32):5958-67. doi: 10.1016/j.vaccine.2007.05.049. [PubMed: 17600596].
  • 24. Cassataro J, Pasquevich K, Bruno L, Wallach JC, Fossati CA, Baldi PC. Antibody reactivity to Omp31 from Brucella melitensis in human and animal infections by smooth and rough Brucellae. Clin Diagn Lab Immunol. 2004;11(1):111-4. [PubMed: 14715555].
  • 25. Diaz AG, Clausse M, Paolicchi FA, Fiorentino MA, Ghersi G, Zylberman V, et al. Immune response and serum bactericidal activity against Brucella ovis elicited using a short immunization schedule with the polymeric antigen BLSOmp31 in rams. Vet Immunol Immunopathol. 2013;154(1-2):36-41. doi: 10.1016/j.vetimm.2013.04.003. [PubMed: 23643287].
  • 26. Cloeckaert A, Baucheron S, Vizcaino N, Zygmunt MS. Use of Recombinant BP26 Protein in Serological Diagnosis of Brucella melitensis Infection in Sheep. Clin Vaccine Immunol. 2001;8(4):772-5. doi: 10.1128/cdli.8.4.772-775.2001.
  • 27. Qiu J, Wang W, Wu J, Zhang H, Wang Y, Qiao J, et al. Characterization of periplasmic protein BP26 epitopes of Brucella melitensis reacting with murine monoclonal and sheep antibodies. PLoS One. 2012;7(3). e34246. doi: 10.1371/journal.pone.0034246. [PubMed: 22457830].
  • 28. Ghasemi A, Ranjbar R, Amani J. In silico analysis of chimeric TF, Omp31 and BP26 fragments of Brucella melitensis for development of a multi subunit vaccine candidate. Iran J Basic Med Sci. 2014;17(3):172-80. [PubMed: 24847419].
  • 29. Sekhavati MH, Heravi RM, Tahmoorespur M, Yousefi S, Abbassi-Daloii T, Akbari R. Cloning, molecular analysis and epitopics prediction of a new chaperone GroEL Brucella melitensis antigen. Iran J Basic Med Sci. 2015;18(5):499-505. [PubMed: 26124937].
  • 30. Cassataro J, Estein SM, Pasquevich KA, Velikovsky CA, de la Barrera S, Bowden R, et al. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection. Infect Immun. 2005;73(12):8079-88. doi: 10.1128/IAI.73.12.8079-8088.2005. [PubMed: 16299302].
  • 31. Yang Y, Wang L, Yin J, Wang X, Cheng S, Lang X, et al. Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine. Mol Immunol. 2011;49(1-2):175-84. doi: 10.1016/j.molimm.2011.08.009. [PubMed: 21943783].
  • 32. Cloeckaert A, Jacques I, Grillo MJ, Marin CM, Grayon M, Blasco JM, et al. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis. Vaccine. 2004;22(21-22):2827-35. doi: 10.1016/j.vaccine.2004.01.001. [PubMed: 15246618].
  • 33. Baldwin CL, Goenka R. Host immune responses to the intracellular bacteria Brucella: does the bacteria instruct the host to facilitate chronic infection?. Crit Rev Immunol. 2006;26(5):407-42. [PubMed: 17341186].
  • 34. Skendros P, Boura P. Immunity to brucellosis. Revue Scientifique et Technique de l'OIE. 2013;32(1):137-47. doi: 10.20506/rst.32.1.2190.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments